Compare DLPN & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLPN | INDP |
|---|---|---|
| Founded | 1996 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6M | 125.2M |
| IPO Year | 2008 | 2021 |
| Metric | DLPN | INDP |
|---|---|---|
| Price | $1.19 | $2.75 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.6K | ★ 1.5M |
| Earning Date | 05-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.87 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $56,699,389.00 | N/A |
| Revenue This Year | $14.73 | N/A |
| Revenue Next Year | $7.41 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 9.70 | N/A |
| 52 Week Low | $1.02 | $0.92 |
| 52 Week High | $1.88 | $8.57 |
| Indicator | DLPN | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 45.78 | 75.24 |
| Support Level | $1.06 | $2.41 |
| Resistance Level | $1.20 | $3.00 |
| Average True Range (ATR) | 0.05 | 0.23 |
| MACD | -0.00 | 0.18 |
| Stochastic Oscillator | 16.60 | 93.75 |
Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing, and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials. The company operates within the U.S.
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.